Advanced Cell Technology's Chief Scientific Officer Delivers Keynote Address at Leading International Stem Cell Conference.LOS ANGELES Los Angeles (lôs ăn`jələs, lŏs, ăn`jəlēz'), city (1990 pop. 3,485,398), seat of Los Angeles co., S Calif.; inc. 1850. -- Advanced Cell Technology, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : ACTC ACTC Apple Certified Technical Coordinator ACTC Almaden Cycle Touring Club ACTC Associated Colleges of the Twin Cities ACTC All Ceylon Tamil Congress (Sri Lanka) ACTC Association Canadienne de Télévision par Câble ) announced today that Dr. Robert Lanza Robert Lanza is is Chief Scientific Officer Advanced Cell Technology (ACT) and Adjunct Professor at the Institute for Regenerative Medicine, Wake Forest University School of Medicine [1]. Lanza received both BA and MD degrees from the University of Pennsylvania. , M.D., the company's Chief Scientific Officer, delivered yesterday the keynote address keynote address n. An opening address, as at a political convention, that outlines the issues to be considered. Also called keynote speech. Noun 1. at the 7th International Stem Cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. Conference, a leading international stem cell conference held October 29-30th in Pittsburgh. The conference featured speakers and presenters from leading stem cell companies and academic researchers. Dr. Lanza was joined as a featured presenter by James F. Battey, Jr., M.D., Ph.D., Director - National Institute on Deafness and Other Communication Disorders The National Institute on Deafness and Other Communication Disorders (NIDCD), a member of the U.S. National Institutes of Health, is mandated to conduct and support biomedical and behavioral research and research training in the normal and disordered processes of hearing, balance, . Dr. Lanza discussed in his address Advanced Cell Technology's new technologies to address immune tolerance issues that are increasingly a focus of the stem cell industry, along with the company's single biopsy technology that was recently identified by the Department of Health and Human Services Noun 1. Department of Health and Human Services - the United States federal department that administers all federal programs dealing with health and welfare; created in 1979 Health and Human Services, HHS as one of the technologies that merits further evaluation for potential financial support. Recently, Advanced Cell Technology announced that the American Heart Association American Heart Association (AHA), n.pr a national voluntary health agency that has the goal of increasing public and medical awareness of cardiovascular diseases and stroke, and thereby reducing the number of associated deaths and disabilities. (AHA) has selected the company's Myoblast myoblast /myo·blast/ (mi´o-blast) an embryonic cell which becomes a muscle cell or fiber.myoblas´tic my·o·blast n. A primitive muscle cell having the potential to develop into a muscle fiber. Phase I(b) trial as a featured late breaking trial for its annual Scientific Sessions Conference in Orlando Florida on November 4, 2007 through November 7, 2007. The AHA's Scientific Sessions Conference is among the premier cardiovascular research and instructional meetings worldwide bringing together interventional cardiologists, electrophysiologists, and nurses and other professionals with content from the forefront of research and clinical practice, including more than 4,000 abstracts of original research and a variety of invited programs. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts. For more information, visit www.advancedcell.com Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion